Company intelligence / Profile preview
Inflammasome Therapeutics
Cambridge, Massachusetts, United Statesinflam.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has completed enrollment in a Phase I PK/Safety study for its lead brain-and-retina penetrant drug K9/Kamuvudine‑9. Early clinical data are not yet published, but the company holds robust IP around NRTIs/Kamuvudines for multiple degenerative diseases.[4]
- Therapeutic areas
- OphthalmologyEndocrinologyNeurologyRheumatology
- Modalities
- Small molecules[3][9]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
University of Kentucky Research Foundation – exclusive worldwide license to foundational patents on Kamuvudines/NRTIs for multiple indications.[7]
Beyond the preview
Go deeper on Inflammasome Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inflammasome Therapeutics.